Location
Philadelphia, PA
Start Date
1-5-2024 1:00 PM
End Date
1-5-2024 4:00 PM
Description
Rosacea, a multifaceted skin condition characterized by facial redness, visible blood vessels, and acne-like bumps, lacks a definitive cure. Treatment options encompass oral medications, topical creams, and laser therapy. To assess the efficacy of combining laser procedures with topical treatments, a systematic review was conducted following PRISMA guidelines. The search, which included databases like PubMed and Embase, identified 496 studies, of which 8 met inclusion criteria.
These studies, involving a total of 200 patients aged between 33.8 to 51.1 years, utilized various combinations of laser therapy and topical agents. Most commonly used lasers included pulsed dye laser (PDL), potassium titanyl phosphate (KTP), neodymium-doped yttrium aluminum garnet (Nd:YAG), and intense pulsed light (IPL). Topical treatments ranged from alpha-adrenergic agonists like oxymetazoline and brimonidine to niacin, ivermectin, and heparan sulfate analog (HSA).
Results showed that combining topical adjuvant medications, particularly alpha-adrenergic agonists, alongside laser therapy yielded positive outcomes with minimal adverse effects. In particular, starting topical medications before laser treatment and continuing their application between laser sessions proved beneficial. Alpha-adrenergic agonists, when used in conjunction with lasers, demonstrated improvement in rosacea appearance compared to baseline and standalone laser treatment.
Additionally, the use of niacin before PDL treatment correlated with reduced erythema. Notably, the adjuvant HSA showcased significant improvement over PDL alone, while ivermectin following PDL did not exhibit similar results. Cutaneous side effects were generally mild and included temporary redness, swelling, itching, and dryness. Adverse events were infrequent, with only 2.8% of patients discontinuing treatment due to side effects.
Although rebound erythema was discussed minimally, the consensus from the studies favored the use of topical adjuvant medications alongside laser therapy due to their potential benefits and favorable safety profile. Overall, the findings suggest a multimodal approach combining both procedural and pharmacologic techniques for more effective management of rosacea.
Embargo Period
6-17-2024
Included in
Lasers and Topical Therapies for the Treatment of Rosacea: A Systematic Review
Philadelphia, PA
Rosacea, a multifaceted skin condition characterized by facial redness, visible blood vessels, and acne-like bumps, lacks a definitive cure. Treatment options encompass oral medications, topical creams, and laser therapy. To assess the efficacy of combining laser procedures with topical treatments, a systematic review was conducted following PRISMA guidelines. The search, which included databases like PubMed and Embase, identified 496 studies, of which 8 met inclusion criteria.
These studies, involving a total of 200 patients aged between 33.8 to 51.1 years, utilized various combinations of laser therapy and topical agents. Most commonly used lasers included pulsed dye laser (PDL), potassium titanyl phosphate (KTP), neodymium-doped yttrium aluminum garnet (Nd:YAG), and intense pulsed light (IPL). Topical treatments ranged from alpha-adrenergic agonists like oxymetazoline and brimonidine to niacin, ivermectin, and heparan sulfate analog (HSA).
Results showed that combining topical adjuvant medications, particularly alpha-adrenergic agonists, alongside laser therapy yielded positive outcomes with minimal adverse effects. In particular, starting topical medications before laser treatment and continuing their application between laser sessions proved beneficial. Alpha-adrenergic agonists, when used in conjunction with lasers, demonstrated improvement in rosacea appearance compared to baseline and standalone laser treatment.
Additionally, the use of niacin before PDL treatment correlated with reduced erythema. Notably, the adjuvant HSA showcased significant improvement over PDL alone, while ivermectin following PDL did not exhibit similar results. Cutaneous side effects were generally mild and included temporary redness, swelling, itching, and dryness. Adverse events were infrequent, with only 2.8% of patients discontinuing treatment due to side effects.
Although rebound erythema was discussed minimally, the consensus from the studies favored the use of topical adjuvant medications alongside laser therapy due to their potential benefits and favorable safety profile. Overall, the findings suggest a multimodal approach combining both procedural and pharmacologic techniques for more effective management of rosacea.